NCT01415882View on ClinicalTrials.gov

Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

PHASE2CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

April 21, 2023

Study Completion Date

April 30, 2025

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Cyclophosphamide

Given PO

BIOLOGICAL

Daratumumab

Given IV

DRUG

Dexamethasone

Given PO or IV

DRUG

Ixazomib Citrate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (3)

55905

Mayo Clinic in Rochester, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER